Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T74456
|
||||
Former ID |
TTDS00267
|
||||
Target Name |
Type-1 angiotensin II receptor
|
||||
Gene Name |
AGTR1
|
||||
Synonyms |
AT1; AT1AR; Angiotensin 1 receptor; Angiotensin II receptor 1; AGTR1
|
||||
Target Type |
Successful
|
||||
Disease | Alzheimer disease [ICD9: 331; ICD10: G30] | ||||
Hypertension [ICD9: 401; ICD10: I10-I16] | |||||
Heart failure [ICD9: 428; ICD10: I50] | |||||
Hypotension [ICD9: 458, 796.3; ICD10: I95] | |||||
High blood pressure [ICD9: 401; ICD10: I10-I16] | |||||
Metabolic syndrome x [ICD9: 277.7; ICD10: E88.81] | |||||
Myocardial infarction [ICD9: 410; ICD10: I21, I22] | |||||
Restenosis [ICD10: I51.89] | |||||
Unspecified [ICD code not available] | |||||
Function |
Receptor for angiotensin II.Mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system.
|
||||
BioChemical Class |
GPCR rhodopsin
|
||||
Target Validation |
T74456
|
||||
UniProt ID | |||||
Sequence |
MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLK
TVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLT CLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNITVC AFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFK IIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPL FYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE |
||||
Drugs and Mode of Action | |||||
Drug(s) | Azilsartan | Drug Info | Approved | Hypertension | [541957], [551719] |
Candesartan | Drug Info | Approved | Hypertension | [536361], [541178] | |
Eprosartan | Drug Info | Approved | Hypertension | [536361], [541182] | |
Forasartan | Drug Info | Approved | Hypertension | [535697], [541952] | |
Irbesartan | Drug Info | Approved | Hypertension | [536095], [541187] | |
Losartan | Drug Info | Approved | Hypertension | [536095], [541193] | |
Micardis telmisartan | Drug Info | Approved | Hypertension | [551881] | |
Olmesartan medoxomil | Drug Info | Approved | High blood pressure | [537312] | |
Saprisartan | Drug Info | Approved | Hypertension | [534931], [541954] | |
SARALASIN | Drug Info | Approved | Hypertension | [541252], [551871] | |
Saralasin Acetate | Drug Info | Approved | Hypertension | [551871] | |
Tasosartan | Drug Info | Approved | Hypertension | [536361], [541953] | |
Telmisartan | Drug Info | Approved | Hypertension | [536361], [541207] | |
Valsartan | Drug Info | Approved | Hypertension | [536361], [540559] | |
Pratosartan | Drug Info | Phase 3 | Hypertension | [545261] | |
S-474474 | Drug Info | Phase 3 | Metabolic syndrome x | [551683] | |
TAK-491 | Drug Info | Phase 3 | Hypertension | [525243] | |
CL-329167 | Drug Info | Phase 2 | Hypertension | [545836] | |
sparsentan | Drug Info | Phase 2 | Myocardial infarction | [527366] | |
TRV027 | Drug Info | Phase 2 | Heart failure | [524481] | |
YM-358 | Drug Info | Phase 2 | Hypertension | [545253] | |
KRH-594 | Drug Info | Discontinued in Phase 2 | Hypertension | [546398] | |
MILFASARTAN | Drug Info | Discontinued in Phase 2 | Hypertension | [545356] | |
RIPISARTAN | Drug Info | Discontinued in Phase 2 | Hypertension | [545748] | |
Zolasartan | Drug Info | Discontinued in Phase 2 | Hypotension | [544984] | |
TAK-591 | Drug Info | Discontinued in Phase 1 | Hypertension | [548747] | |
UR-7198 | Drug Info | Discontinued in Phase 1 | Hypertension | [546845] | |
CR-3834 | Drug Info | Terminated | Hypertension | [548162] | |
HELENALIN | Drug Info | Terminated | Discovery agent | [544640] | |
L-159689 | Drug Info | Terminated | Hypertension | [545497] | |
RS-66252 | Drug Info | Terminated | Alzheimer disease | [546339] | |
UP-275-22 | Drug Info | Terminated | Hypertension | [545814] | |
XR-510 | Drug Info | Terminated | Hypertension | [545812] | |
Antagonist | (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n | Drug Info | [534913] | ||
4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone | Drug Info | [534957] | |||
4-[(diphenylmethyl)amino]-2-phenylquinazoline | Drug Info | [535513] | |||
5-butyl-methyl immidazole carboxylate 30 | Drug Info | [532000] | |||
5-oxo-1-2-4-oxadiazol biphenyl | Drug Info | [531841] | |||
Candesartan | Drug Info | [535067], [537549] | |||
CL-329167 | Drug Info | [533874], [551871] | |||
CR-3834 | Drug Info | [529503] | |||
Eprosartan | Drug Info | [536887] | |||
EXP3174 | Drug Info | [533998] | |||
Forasartan | Drug Info | [535264], [535697] | |||
GBR-12935 | Drug Info | [538041] | |||
Irbesartan | Drug Info | [537449] | |||
KRH-594 | Drug Info | [526535] | |||
Losartan | Drug Info | [534973], [535660], [537449] | |||
LY301875 | Drug Info | [526029] | |||
LY303336 | Drug Info | [526029] | |||
Micardis telmisartan | Drug Info | [527783] | |||
MILFASARTAN | Drug Info | [532043], [551871] | |||
N,N`-bis-alkyl butylimmidazole 12b | Drug Info | [532215] | |||
Olmesartan medoxomil | Drug Info | [537475] | |||
Pratosartan | Drug Info | [529390] | |||
RIPISARTAN | Drug Info | [533666], [551871] | |||
Saprisartan | Drug Info | [534931] | |||
sparsentan | Drug Info | [527799] | |||
TAK-591 | Drug Info | [551717] | |||
Tasosartan | Drug Info | [535061] | |||
Telmisartan | Drug Info | [537265] | |||
TRV027 | Drug Info | [532415] | |||
UR-7198 | Drug Info | [525714] | |||
Valsartan | Drug Info | [535660], [537449] | |||
YM-358 | Drug Info | [525713], [551871] | |||
[125I]EXP985 | Drug Info | [526828] | |||
[3H]A81988 | Drug Info | [533927] | |||
[3H]candesartan | Drug Info | [525439] | |||
[3H]eprosartan | Drug Info | [534043] | |||
[3H]irbesartan | Drug Info | [526320] | |||
[3H]L158809 | Drug Info | [526960] | |||
[3H]losartan | Drug Info | [533967] | |||
[3H]valsartan | Drug Info | [525979] | |||
Inhibitor | 4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol | Drug Info | [551262] | ||
ANGIOTENSIN II | Drug Info | [530710] | |||
Carboxylic Acid Metabolite (E-3174) | Drug Info | [551260] | |||
CV-11194 | Drug Info | [534298] | |||
GNF-PF-2307 | Drug Info | [531262] | |||
GNF-PF-2812 | Drug Info | [531262] | |||
GNF-PF-3832 | Drug Info | [531262] | |||
HELENALIN | Drug Info | [531262] | |||
L-159093 | Drug Info | [527799] | |||
L-159689 | Drug Info | [527799] | |||
L-162313 | Drug Info | [529578] | |||
L-162782 | Drug Info | [529578] | |||
SARALASIN | Drug Info | [529569] | |||
[Bpa1]AngII | Drug Info | [530710] | |||
[Sar1,Bpa2]AngII | Drug Info | [530710] | |||
[Sar1,Bpa3]AngII | Drug Info | [530710] | |||
[Sar1,Bpa8]AngII | Drug Info | [530710] | |||
[Sar1,Tdf2]AngII | Drug Info | [530710] | |||
[Sar1,Tdf3]AngII | Drug Info | [530710] | |||
[Sar1,Tdf8]AngII | Drug Info | [530710] | |||
[Tdf1]AngII | Drug Info | [530710] | |||
Agonist | angiotensin III | Drug Info | [543777] | ||
L-163,101 | Drug Info | [534516] | |||
Zolasartan | Drug Info | [531650] | |||
Modulator | Azilsartan | Drug Info | [531783] | ||
CGP-49870 | Drug Info | ||||
RS-66252 | Drug Info | [551841] | |||
Saralasin Acetate | Drug Info | [556264] | |||
TAK-491 | Drug Info | [531783] | |||
UP-275-22 | Drug Info | [543777] | |||
XR-510 | Drug Info | [534102] | |||
Blocker | S-474474 | Drug Info | [551683] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Calcium signaling pathway | ||||
cGMP-PKG signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Adrenergic signaling in cardiomyocytes | |||||
Vascular smooth muscle contraction | |||||
Renin-angiotensin system | |||||
Renin secretion | |||||
Pathways in cancer | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
PANTHER Pathway | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | ||||
Pathway Interaction Database | Arf6 trafficking events | ||||
Arf6 signaling events | |||||
Angiopoietin receptor Tie2-mediated signaling | |||||
PathWhiz Pathway | Angiotensin Metabolism | ||||
Muscle/Heart Contraction | |||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (q) signalling events | |||||
WikiPathways | ACE Inhibitor Pathway | ||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
Peptide GPCRs | |||||
Allograft Rejection | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
Ref 524481 | ClinicalTrials.gov (NCT01966601) A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure. U.S. National Institutes of Health. | ||||
Ref 525243 | ClinicalTrials.gov (NCT02480764) TAK-491 (Azilsartan Medoxomil) Compared to Valsartan in Chinese Participants With Hypertension. | ||||
Ref 527366 | Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1):171-9. | ||||
Ref 534931 | Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. | ||||
Ref 535697 | Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26. | ||||
Ref 536095 | New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 537312 | Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5(1):301-14. Epub 2009 Apr 8. | ||||
Ref 540559 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3937). | ||||
Ref 541178 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 587). | ||||
Ref 541182 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 588). | ||||
Ref 541187 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 589). | ||||
Ref 541193 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 590). | ||||
Ref 541207 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 592). | ||||
Ref 541252 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 598). | ||||
Ref 541952 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6896). | ||||
Ref 541953 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6898). | ||||
Ref 541954 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6899). | ||||
Ref 541957 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6901). | ||||
Ref 544640 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000398) | ||||
Ref 544984 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001788) | ||||
Ref 545253 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002583) | ||||
Ref 545261 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002623) | ||||
Ref 545356 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002993) | ||||
Ref 545497 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003495) | ||||
Ref 545748 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004530) | ||||
Ref 545812 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004861) | ||||
Ref 545814 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004864) | ||||
Ref 545836 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004990) | ||||
Ref 546339 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007561) | ||||
Ref 546398 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007913) | ||||
Ref 546845 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010597) | ||||
Ref 548162 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022642) | ||||
Ref 548747 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028308) | ||||
Ref 525439 | Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur J Pharmacol. 1999 Feb 19;367(2-3):413-22. | ||||
Ref 525713 | Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81. | ||||
Ref 525714 | Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. J Cardiovasc Pharmacol. 2000 Mar;35(3):383-9. | ||||
Ref 525979 | Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fundam Clin Pharmacol. 2000 Nov-Dec;14(6):577-85. | ||||
Ref 526029 | Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors. Pharm Res. 2000 Dec;17(12):1482-8. | ||||
Ref 526320 | Binding characteristics of [(3)H]-irbesartan to human recombinant angiotensin type 1 receptors. J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2):159-65. | ||||
Ref 526535 | Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. Fundam Clin Pharmacol. 2002 Aug;16(4):317-23. | ||||
Ref 526828 | [125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT1 angiotensin receptor. Biochem Biophys Res Commun. 1992 Nov 16;188(3):1030-9. | ||||
Ref 526960 | Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. Mol Pharmacol. 1992 Dec;42(6):1077-82. | ||||
Ref 527783 | The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005 Nov;23(11):2055-61. | ||||
Ref 527799 | J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm. | ||||
Ref 529390 | Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7. | ||||
Ref 529503 | Pharmacokinetic study of a new angiotensin-AT1 antagonist by HPLC. J Pharm Biomed Anal. 2008 Sep 29;48(2):422-7. | ||||
Ref 529569 | J Med Chem. 2008 Jul 24;51(14):4150-69. Epub 2008 Jun 28.Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. | ||||
Ref 529578 | Bioorg Med Chem. 2008 Jul 15;16(14):6841-9. Epub 2008 Jul 1.Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. | ||||
Ref 530710 | J Med Chem. 2010 Mar 11;53(5):2063-75.The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. | ||||
Ref 531262 | Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). | ||||
Ref 531650 | Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev. 2011 Nov-Dec;19(6):300-4. | ||||
Ref 531841 | Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect. Bioorg Med Chem. 2012 Apr 15;20(8):2747-61. | ||||
Ref 532000 | The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem. 2012 Sep;55:358-74. | ||||
Ref 532043 | Dual action molecules: bioassays of combined novel antioxidants and angiotensin II receptor antagonists. Eur J Pharmacol. 2012 Nov 15;695(1-3):96-103. | ||||
Ref 532215 | Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. Eur J Med Chem. 2013 Apr;62:352-70. | ||||
Ref 532415 | First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2013 Sep;53(9):892-9. | ||||
Ref 533666 | In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundam Clin Pharmacol. 1995;9(2):119-28. | ||||
Ref 533874 | Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994 Aug;267(2 Pt 2):H844-52. | ||||
Ref 533927 | [3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994 Mar 15;267(1):49-54. | ||||
Ref 533967 | Characterization of [3H]losartan receptors in isolated rat glomeruli. Eur J Pharmacol. 1993 Oct 15;247(2):193-8. | ||||
Ref 533998 | Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993 Jun;45(2):205-51. | ||||
Ref 534043 | Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor. J Recept Res. 1993;13(5):849-61. | ||||
Ref 534102 | Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. J Cardiovasc Pharmacol. 1995 Sep;26(3):354-62. | ||||
Ref 534298 | J Med Chem. 1996 Dec 20;39(26):5228-35.Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. | ||||
Ref 534516 | Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol. 1994 Dec;1(4):211-21. | ||||
Ref 534913 | Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther. 1999 Nov;291(2):648-54. | ||||
Ref 534931 | Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. | ||||
Ref 534957 | Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J Med Chem. 2000 Feb 10;43(3):351-60. | ||||
Ref 534973 | Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol. 2000 Feb;119(2-3):189-97. | ||||
Ref 535061 | Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. | ||||
Ref 535067 | Angiotensin II type 1 receptor blockade: a novel therapeutic concept. Blood Press Suppl. 2000;1:9-13. | ||||
Ref 535264 | Possible involvement of calcium-calmodulin pathways in the positive chronotropic response to angiotensin II on the canine cardiac sympathetic ganglia. Jpn J Pharmacol. 2001 Aug;86(4):381-9. | ||||
Ref 535513 | Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8. | ||||
Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
Ref 535697 | Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26. | ||||
Ref 536887 | Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. | ||||
Ref 537265 | Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35. Epub 2009 Mar 11. | ||||
Ref 537449 | Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. | ||||
Ref 537475 | Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56. | ||||
Ref 537549 | Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. | ||||
Ref 538041 | Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol. 1997 Jun 15;53(12):1937-9. | ||||
Ref 543777 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34). | ||||
Ref 551260 | Angiotensin II receptor antagonists: imidazoles and pyrroles bearing hydroxymethyl and carboxy substituents, Bioorg. Med. Chem. Lett. 4(1):177-182 (1994). | ||||
Ref 551262 | Discovery and development of aryl-fused imidazole-based angiotensin II antagonists, Bioorg. Med. Chem. Lett. 4(1):213-218 (1994). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.